September 09, 2021
The UCLA Center for Clinical AIDS Research & Education (CARE), UCLA Pacific AIDS Education Training Center (PAETC), UCLA AIDS Institute, and Center for HIV Identification, Prevention and Treatment Services (CHIPTS) proudly present the 18th Annual HIV CME Symposium "Tough Decisions Made Easier: Clinical Management of Treatment - Experienced Patients." This one-day virtual symposium is designed to
August 12, 2021
When the antiretroviral regimen known as pre-exposure prophylaxis, or PrEP, was launched nearly a decade ago, patients were suddenly able to achieve near-complete protection against contracting HIV by taking just one pill a day. Full news release on www.usnews.com
July 30, 2021
“Weight gain and the chronic conditions to which it often leads can have detrimental effects on the health and quality of life of people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles. “The ACTG is committed to undertaking research that optimizes ARV treatment and ensures optionality for people living with HIV.” Full news release on www.mir
The primary purpose of this study is to see if people with HIV who had a significant weight gain after starting INSTI (integrase strand transfer inhibitor)+TAF/FTC (tenofovir alafenamide/emtricitabine) (TAF/3TC [lamivudine]) regimen could either slow their rate of weight gain or lose weight within about 1 year if they switch to a regimen containing doravirine (DOR; a newer, non-nucleoside reverse transcriptase inhibitor medication). Interested in Volunteering? Have you experienced weight gain while on antiretroviral therapy? The Do It Study is looking for people living with HIV who have experienced weight gain from taking a treatment regimen that contains an integrase inhibitor like Tivicay, Issentress, or (one of the drugs contained in Biktarvy) plus tenofovir alafenamide (TAF) Basic Eligibility Requirement: Age 18+ Living with HIV Currently on an ART regimen containing an integrase inhibitor and TAF without interruption over 48 weeks Experienced >10% weight gain in 1-3 years after starting these medications Have a body mass index (BMI) > 27.5 Principal Investigator: Raphael J. Landovitz, MD, MSc For more information, please contact the UCLA CARE Center: [email protected] 310-843-2015 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
HVTN 136/HPTN 092 is a phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous or subcutaneous infusions in healthy adults who do not have HIV. Interested in Volunteering? Are you interested in advancing the science of HIV Prevention, or have your loved ones been impacted by HIV? We have an exciting opportunity for YOU to help move research forward for HIV PREVENTION. Antibodies are proteins the body makes to help fight disease in response to exposure to avirus. The body is constantly creating antibodies to help prevent illnesses. In this study, participants will receive investigational antibodies to see if this could be a new PrEP or HIV prevention treatment in the future. We need volunteers who are: 18-50 years old HIV-negative At low-risk for HIV-infection In good general health Principal Investigator: Raphael Landovitz, MD, MSc For more information, contact the UCLA CARE Center at: [email protected] 310-557-9062 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI). Interested in Volunteering? We are looking for HIV+ people who are taking antiretroviral treatment (ART) and whose viral load is undetectable. The goal is to find out if IL-15 is safe alone or when used in combination with another treatment called broadly neutralizing antibodies (bNAbs). Participants will receive 8 doses of IL-15 given every 3 weeks. Half of the participants will be randomly assigned to also receive the bNAbs with it. After completing these treatments, participants will temporarily stop taking their HIV medicine (ART) and will be evaluated to see how well this treatment controls their viral load. Basic Eligibility Criteria: Age: 18-65 years old Status: HIV Positive Continuous HIV treatment: at least 96 weeks Viral load: Undetectable at least 96 weeks Coinfection: No active hepatitis B or C infection CD4 count: More than 500 Principal Investigator: Kara Chew, MD, MS For more information, please contact the UCLA CARE Center: [email protected] 310-843-2015 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.